2023 World Conference on Lung Cancer (Posters)-P1.23. Extracellular Small Vesicle Phosphorylated PD-L1 Liquid Biopsy Levels Correlate with Tumour Proportion Score (TPS) in NSCLC

P1.23. Extracellular Small Vesicle Phosphorylated PD-L1 Liquid Biopsy Levels Correlate with Tumour Proportion Score (TPS) in NSCLC - PDF(Slides)

Back to course

Pdf Summary

Researchers at Princess Alexandra Hospital and Queensland University of Technology in Australia have developed a highly sensitive blood test capable of detecting phosphorylated programmed death receptor ligand 1 (PD-L1) in extracellular small vesicles. PD-L1 is a protein expressed on the surface of cancer cells that inhibits the immune response. Immune checkpoint inhibitors that target PD-L1 have shown promising results in treating non-small cell lung cancer (NSCLC). However, current methods of determining PD-L1 expression, such as tissue biopsies, are invasive and sometimes limited by the location of the tumor or patient fitness. <br /><br />The study aimed to determine the correlation between extracellular small vesicle phosphorylated PD-L1 (EV pPD-L1) levels in liquid biopsies and the Tumor Proportion Score (TPS) in NSCLC. The researchers collected plasma samples from 65 patients with NSCLC and extracted EV pPD-L1. PD-L1 levels were measured using a highly sensitive platform capable of detecting PD-L1 isoforms. The study found a correlation between EV pPD-L1 levels and TPS, regardless of tumor stage or burden. However, plasma PD-L1 levels did not correlate with the TPS score. <br /><br />The researchers developed a mesoporous gold microchip for the detection of pPD-L1 in EVs. This biosensor could accurately and reliably differentiate PD-L1 isoforms in plasma. The adsorption of phosphorylated proteins on the gold surface was quantified using differential pulse voltammetry. <br /><br />The study demonstrated the potential of using EV pPD-L1 as a non-invasive biomarker for determining PD-L1 expression in NSCLC patients. The findings suggest that liquid biopsies may provide valuable information for identifying patients who are likely to respond to anti-PD-1/PD-L1 therapy. The researchers also highlighted the versatility of the microchip in profiling phosphorylation pathways in lung cancer.

Asset Subtitle

Kenneth O'Byrne

Meta Tag

Speaker Kenneth O'Byrne

Topic Pathology & Biomarkers: Liquid Based Biomarkers

Keywords

blood test

PD-L1

extracellular small vesicles

immune response

immune checkpoint inhibitors

non-small cell lung cancer

liquid biopsies

Tumor Proportion Score

mesoporous gold microchip

phosphorylation pathways